Genoskin Funding Round

9/16/2025

Debt
Venture Equity

$8,700,000

Series A

The company intends to use the funds to drive its next phase of growth and support further staff recruitment, with a view to double the size of the company within the next three years and to expand its commercial presence in key global markets.

Private & Independent

Biopharmaceutical

Undisclosed
Toulouse, Undisclosed
France

Undisclosed

Not Recorded

Genoskin offers unmatched expertise in skin biology and immunology to support your research and drug development. Our mission is to generate reliable human data before regulatory studies for therapeutics, vaccines, medical devices, cosmetics, and chemicals. Using donated human skin, we preserve its viability for up to seven days post-surgery with our proprietary patented technology--allowing comprehensive testing across all cell types and skin structures. Unlike animal or engineered models, our platforms provide authentic, human-relevant data. With advanced assays, including imaging techniques and next-generation sequencing, combined with deep scientific expertise, we equip you with the data needed to accelerate your projects with confidence and precision.